Recent Progress in Nutrition (ISSN 2771-9871) is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. This periodical is devoted to publishing high-quality papers that describe the most significant and cutting-edge research in all areas of nutritional sciences. Its aim is to provide timely, authoritative introductions to current thinking, developments and research in carefully selected topics. Also, it aims to enhance the international exchange of scientific activities in nutritional science and human health.

Recent Progress in Nutrition publishes high quality intervention and observational studies in nutrition. High quality systematic reviews and meta-analyses are also welcome as are pilot studies with preliminary data and hypotheses generating studies. Emphasis is placed on understanding the relationship between nutrition and health and of the role of dietary patterns in health and disease.

Topics contain but are not limited to:

  • Macronutrients
  • Micronutrients
  • Essential nutrients
  • Bioactive nutrients
  • Nutrient requirements
  • Nutrient sources
  • Human nutrition aspects
  • Functional foods
  • Nutraceuticals
  • Health claims
  • Public health
  • Diet-related disorders
  • Metabolic syndrome
  • Malnutrition
  • Nutritional supplements
  • Sport nutrition

It publishes a variety of article types: Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.

There is no restriction on paper length, provided that the text is concise and comprehensive. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.

Publication Speed (median values for papers published in 2023): Submission to First Decision: 6.7 weeks; Submission to Acceptance: 16.1 weeks; Acceptance to Publication: 6 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021
Open Access Short Review

The Role of Vitamin D for Children with Inflammatory Bowel Disease

Angharad Vernon-Roberts †,*, Andrew S Day 

Department of Paediatrics, University of Otago, Christchurch, New Zealand

† These authors contributed equally to this work.

Correspondence: Angharad Vernon-Roberts

Academic Editor: Sakineh Shab-Bidar

Special Issue: Vitamin D Status and Its Relation to Energy Expenditure, Chronic Disease and Health Status

Received: January 23, 2022 | Accepted: April 13, 2022 | Published: April 19, 2022

Recent Progress in Nutrition 2022, Volume 2, Issue 2, doi:10.21926/rpn.2202013

Recommended citation: Vernon-Roberts A, Day AS. The Role of Vitamin D for Children with Inflammatory Bowel Disease. Recent Progress in Nutrition 2022;2(2):013; doi:10.21926/rpn.2202013.

© 2022 by the authors. This is an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.


Children with inflammatory bowel disease (IBD) have a high prevalence of vitamin D insufficiency secondary to factors such as malabsorption and decreased intake. In recent years the benefits of optimal vitamin D status have been highlighted for their potential to improve the disease course and long-term outcomes in this population. Clinical benefits have been seen to bone health, the immune system, and gut health, with further improvements to disease and treatment outcomes. Recommendations for vitamin D treatment parameters to optimize these benefits have been developed, as well as the identification of risk factors for insufficiency specific to children with IBD. While various supplementation regimens are available reports of efficacy are inconsistent, as are guidelines for frequency of testing. Further research is required to elucidate whether hypovitaminosis D is a cause or consequence of IBD, and the role of vitamin D supplementation in treatment warrants significant attention.


Vitamin D; bone health; hypovitaminosis D; immunomodulatory; supplementation; children; inflammatory bowel disease

1. Introduction

The incidence of inflammatory bowel disease (IBD) is rising globally and with up to 25% of IBD cases developing during childhood or adolescence it has become one of the most important and serious chronic diseases of childhood [1,2,3]. Childhood-onset IBD is typically more severe with more extensive disease and a more complex progression than IBD diagnosed as an adult [4,5]. Consequently, IBD in childhood can have detrimental effects on growth, developmental, and cognitive trajectories.

The term IBD incorporates the clinical sub-types of Crohn’s disease (CD) and ulcerative colitis (UC), both of which are complex, relapsing inflammatory conditions of the gastrointestinal tract. CD is defined as a transmural, segmental condition that may occur in any part of the gut, while UC involves continuous involvement of the mucosal and submucosal layers of the colon [6]. The pathogenesis of IBD is a result of the interplay between the mechanisms of environmental factors, immune response, intestinal barrier, and genetics. Genome-wide association studies have identified over 200 genetic risk loci associated with IBD, of which some are specific to CD, some specific to UC, but many associated with both sub-types, indicating that these diseases share common inflammatory pathways [7].

Micronutrient deficiencies are commonly observed in children with IBD, predominantly attributable to malabsorption and/or decreased intake. Although some micronutrient deficiencies are dependent on disease location, medications or surgery, overall the most common reported deficiencies are of iron, vitamin D and calcium with further deficits in essential fatty acids, and water/fat soluble vitamins [8,9,10,11]. These deficiencies are particularly problematic when IBD is diagnosed during childhood as it is a critical period of growth and development.

A focus of recent global research has been on the importance of vitamin D specifically and the role it plays in the disease course of individuals with IBD. This mini-review aims to highlight the significance of optimal vitamin D status (as measured by the serum concentration of 25-hydroxyvitamin D (25(OH)D) for children with IBD, as well as the efficacy of various treatment options in managing sub-optimal 25(OH)D concentrations. Literature was identified from comprehensive topic-specific searches of health databases (Medline, Embase) alongside reference list reviews of relevant studies.

2. Vitamin D

2.1 Overview

Vitamin D is a liposoluble nutrient with two major physiologically relevant forms; ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), both of which are provided from the diet, and also can be fortified in some food products [12,13]. Vitamin D3 is also cutaneously synthesized under the influence of ultraviolet (UV) light [14]. Vitamin D insufficiency or deficiency may occur secondary to reduced synthesis during winter months when there are fewer sunshine hours [15], and due to western diets being a poor source of vitamin D [16]. Subsequently, sub-optimal 25(OH)D concentrations are seen in populations around the world [15]. The physiological effects of optimal vitamin D status for children with IBD are multifactorial and have garnered interest for their potential to ameliorate the effects of the disease. Benefits have been seen in parameters relating to bone health, the immune system, the gut, treatment efficacy, and clinical outcomes.

Vitamin D status is assessed by measuring serum or plasma concentrations of the metabolite 25-hydroxyvitamin D (25-OH-D), a reliable marker of dietary intake and cutaneous synthesis [17,18]. The consensus of an optimal serum concentration of 25(OH)D has varied over time. However, it is currently considered that a concentration of ≥75 nmol/l (≥30 ng/ml) may be required for children with IBD in order to achieve benefits to the immune system, bone health, and clinical outcomes [19,20,21]. A commonly used term for vitamin insufficiency or deficiency is ‘hypovitaminosis’, and will be referred to herein.

2.2 Clinical Benefits

2.2.1 Bone Health

Vitamin D is essential to bone health throughout the life-span. Adequate serum concentrations are needed to optimize intestinal absorption of calcium, and for maintenance of the serum calcium/phosphate balance required for calcification of the growth plate and mineralization of osteoid in cortical and trabecular bone [18,22]. The importance of this process is highlighted in previous work that demonstrated prolonged vitamin D deficiency resulted in delayed growth and rickets in healthy children as well as osteoporosis and osteopenia in adults [23].

The prevalence of poor bone health, manifesting as low bone mineral density (BMD), is high among children with IBD and comes during a period in their lives when bone mass acquisition should be most rapid [24,25]. Subsequent failure to attain peak bone mass by adulthood is disadvantageous and has been linked with increased risk of fractures during childhood and in later life [24,26,27]. The pathogenesis of low BMD among children with IBD is complex and suboptimal vitamin D is just one contributing factor. Other risk factors include medications, chronic inflammation, delayed puberty, decreased growth factors, decreased physical activity, low BMI, and malnutrition [24,25].

A number of studies have reported BMD and the association with 25(OH)D concentrations in children with IBD. In all cohorts studied, children with IBD had subnormal BMD, or levels significantly lower than controls [28,29,30,31,32], however, the role of vitamin D in this process was less clear. Conflicting results were seen, with some studies reporting a positive association between BMD and vitamin D [28,30], while others showed no correlation [29,31]. Vitamin D supplementation was shown to accelerate accrual of BMD in two studies [28,32], with contrasting results found in another [33]. The disparity in these results may be due to the fact that bone mineral accretion is normally cumulative and, therefore, measuring vitamin D at a single time point may not correlate well with a single measurement of BMD [34]. In addition, children with IBD can be shown to have low BMD and vitamin D at the time of diagnosis and this does not necessarily improve longitudinally following treatment, thereby limiting the assumptions that can be made regarding normal bone mass acquisition [9,31,35]. A meta-analysis of studies among healthy children aiming to assess efficacy of vitamin D supplementation on BMD showed no significant effect with BMD measured at a number of sites (total hip, forearm, lumbar-spine) [36]. When sub-group analyses were carried out on studies including participants with low baseline 25(OH)D concentrations the only effect seen was of borderline significance in one study for improvements to bone mineral content [36]. Consequently, while disease variables for children with IBD may negatively affect their BMD the possibility of improvement with the use of vitamin D supplementation is by no means guaranteed, especially in combination with other contributing factors.

2.2.2 Immunomodulatory Effect

In addition to its association with bone health, vitamin D plays a diverse and dynamic role upon the gut microbiota, as well as regulating adaptive and innate immunity. Optimal serum concentrations may play a protective role in the onset and clinical course of IBD [12,20,37]. It has been shown that vitamin D3 induces nucleotide-binding oligomerization domain protein (NOD2) gene expression, and exerts different effects on the expression of toll-like receptor (TLR) and NOD2 induced cytokines in CD [38]. The intestinal microbiota and its metabolites act on both NOD1 and NOD2 receptors, and their defective signaling may contribute to the onset of IBD [38,39]. In relation to the clinical course of IBD, one mechanism by which vitamin D plays a role is through altering the immune response. T lymphocytes contain vitamin D receptors that are both direct and indirect targets of the micronutrient [40]. Vitamin D is crucial to activation of T cells, but also indirectly alters inflammation by affecting antigen-presenting cells. Dendritic cells and macrophages that are treated with vitamin D3 decrease their secretion of pro-inflammatory cytokines following activation; the resultant modulation of differentiation and maturation promotes the induction of T cells with regulatory phenotypes [12,38,40].

2.2.3 Gut Health

Children with IBD commonly have increased permeability of the intestinal barrier, which has been associated with inflammation and dysbiosis due to increased exposure of the immune system to the intestinal microbiota [13,40]. Vitamin D benefits gut health by targeting three major components of the gastrointestinal tract: the intestinal epithelial barrier, gut immunity, and gut microbiota [12]. Vitamin D signaling is imperative in maintaining the integrity of the epithelial barrier by protecting against infectious and inflammatory insults in a number of ways: by increasing its resistance to irritants in the intestinal mucosa, suppressing epithelial cell apoptosis, enhancing repair, and increasing the expression of specific tight junction proteins [12,40]. In addition, vitamin D promotes a rich and diverse gut microbiome, with high dose supplementation shown to lead to increased bacterial richness in the gastrointestinal tract [12,41]. Consequently, sub-optimal concentrations of 25(OH)D may negatively affect the gut barrier and immune function and lead to increased dysbiosis and potential translocation of gut bacteria, thus affecting IBD onset and progression [13,42]. Much of the research relating to gut integrity is in vitro, but low concentrations of 25(OH)D have been shown to inversely correlate with surrogate markers of gut inflammation such as fecal calprotectin [43,44,45,46], as well as tumor necrosis factor (TNF) and other pro-inflammatory cytokines [43].

2.2.4 Disease Outcomes

Vitamin D sufficiency has been linked to a number of clinical benefits for children with IBD, in particular the role vitamin D plays in moderating disease activity. While a small number of studies have observed lower disease activity among children with sufficient, or higher, vitamin D levels [47,48,49,50], the few studies available on vitamin D supplementation that reported on disease activity also suggest a beneficial effect on these specific clinical indices. A double blind, placebo controlled RCT to treat hypovitaminosis D showed that supplementation significantly reduced disease activity indices, relapse frequency, disease severity score, and a number of inflammatory markers: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fecal calprotectin, TNF-α, and the inter-leukins (IL) IL-17, 10, 12, and 23 [43]. In addition, this study reported benefits to quality of life, along with reduced hospitalizations and emergency department visits [43]. Retrospective reviews have also reported benefit to disease activity indices, [51,52], CRP [51,53], ESR [51,53], and IL-6 [53], although all at different dosing regimens.

A number of meta-analyses on vitamin D supplementation have been performed, however, most comprise either predominantly adults with IBD, or included the pediatric studies cited above. Overall, the relapse rate and/or disease activity scores were significantly reduced using vitamin D supplementation in four analyses [54,55,56,57], but not in one [58]. A significant reduction of CRP was seen in two analyses [56,58] but no change in ESR [55,58] or CRP [55] in others. All analyses reported significant bias in many of their included studies, and the vitamin D dosing regimens were not consistent.

2.2.5 Treatment Outcomes

In addition to the benefits previously highlighted, vitamin D may play a beneficial role in the response of children with IBD to anti-TNF medications, which are an effective treatment for CD and UC. Anti-TNF primary nonresponse, or loss of response, poses a significant problem but vitamin D sufficiency may ameliorate this. Studies have reported that children and adults with IBD on anti-TNF therapy with vitamin D insufficiency had significantly higher levels of early treatment termination due to loss of response [19,41,59]. Another report indicated decreased odds of being in remission following induction in subjects with insufficiency compared to those that were vitamin D sufficient [60]. In addition, when those treated with an anti-TNF therapy were given vitamin D supplementation remission rates were higher for those with greater 25(OH)D concentrations [44]. It is hypothesized that the way in which vitamin D affects disease severity is via the TNF pathway, with genome-wide analysis revealing that 25(OH)D concentrations influence a large number of genes [37,60]. These data suggest anti-TNF medications and vitamin D may be synergistic in decreasing TNF levels, thereby suggesting an adjunctive role of vitamin D in IBD treatment regimens.

2.3 Vitamin D Concentrations in the Setting of IBD in Children

Vitamin D deficiency among the general pediatric population has been defined in a number of ways in the literature. In guidelines from Central Europe, Australasia, and the Americas moderate and severe deficiency is defined as serum 25(OH)D concentrations less than 50 nmol/L and 30 nmol/L respectively, and insufficiency as between 51 and 75 nmol/L [14,61,62,63]. Other work in Europe defines the cutoff for deficiency as 50 nmol/L [14,61,64]. When studies specific to children with IBD are examined there is considerable variation in terminology, units of measurement, and concentration cut-offs, even within geographic areas (Table 1). Inferences on the proportion of children with IBD and hypovitaminosis D is, therefore, complex with prevalence up to 81% of individuals being below the recommended range by definition (Table 1).

Table 1 Vitamin D cut-off definitions and prevalence of deficiencies among individual studies.

A number of systematic reviews that included children with IBD, and additional pediatric studies, report that overall the serum concentrations of 25(OH)D in children with IBD are lower than controls [42,47,54,69]. However, this was not evident in two individual studies [65,71]. Evidence to determine whether there is a difference in concentrations between the IBD clinical sub-types is lacking, with one study reporting children with UC having significantly lower vitamin D than children with CD some reporting no difference, and many not comparing the groups (Table 1).

2.3.1 Risk Factors for Hypovitaminosis D

A number of disease-related risk factors for hypovitaminosis D have been identified for children with IBD, with additional factors that are also relevant to the general population. The magnitude of exposure to corticosteroids has been shown to negatively affect 25(OH)D concentrations [18,67], as well as factors relating to a reduced intake and absorption of vitamin D such as reduced appetite, malnutrition, and gastrointestinal (GI) losses [8,24]. Disease activity, whether classified by increased inflammatory markers or clinical indices, may be associated with sub-optimal vitamin D [47,49,50]. Furthermore, a number of studies have reported increased risk of low 25(OH)D concentrations in children with upper gastrointestinal CD [18,20,24,48,72]. Poor growth as represented by a low body mass index (BMI) score was shown to be a risk factor in one study [48], with the opposite found in other research with a high BMI being a risk factor [68,71] likely due to a greater proportion of the body’s vitamin D being stored in adipose tissue [17].

Risk factors common to children with IBD as well as the general population are well reported. Low exposure to UV light is a significant cause of hypovitaminosis D that could be consequent to reduced outdoor activities as a consequence of IBD symptomatology [42]. Other factors such as darker skin pigmentation, age, and use of sunscreen may reduce the effective exposure to UV light of the vitamin D precursor [15,18,68,73]. Seasonal variations in 25(OH)D concentrations during winter months are well reported as there is insufficient UV light exposure to allow cutaneous synthesis [18,68]. In addition, the latitude at which people reside exerts an influence as the skin synthesizes lower levels of vitamin D from sun exposure at latitudes 37° north or south of the equator [15,40]. Further evidence of this link is seen in the emerging global gradient of IBD with higher incidence rates in more northern or southern countries, as well as within-country gradients [74,75,76,77,78,79].

While work has been carried out confirming that genetic polymorphisms and alterations are related to vitamin D status, the underlying genetic determinants remain poorly understood [80]. Additional research is needed in order to clarify these genetic determinants, and to examine the mechanisms of action responsible for the association with vitamin D status that may identify susceptible individuals who may benefit from supplementation [80].

The main prevention strategy for vitamin D insufficiency within the population of children with IBD should be to identify those at risk according to the criteria outlined above, and to correct and optimize their 25(OH)D concentrations, as below.

2.4 Correction of Hypovitaminosis D

In order to correct and optimize 25(OH)D concentrations for children with IBD a number of strategies may be applied relating to environmental factors, dietary intake, and clinical treatment. Vitamin D may be obtained from two sources: UV mediated synthesis and oral intake. UV exposure accounts for 80% to 90% of vitamin D in the human body [15], but if there is inadequate exposure to sunlight then support from diet and/or supplements is fundamental to achieve optimal concentrations [13,17,24]. Education on the importance of including vitamin D rich foods in the diet is beneficial, with recommendations from the European Food Safety Authority being for a daily intake of 1000 IU/day for infants 0 to 12 months, 2000 IU/day for children ages 1 to 10 years, and 4000 IU/day for children ages 11 to 17 years of vitamin D [64]. While few foods contain substantial amounts, sources with high levels include: oily fish, eggs, beef liver, as well as fortified products such as milk, juices, breads, and cereals [13,24]. However, with only 20% of daily vitamin D needs being met through diet, and children with IBD experiencing risk factors that may contribute to further reduced intake or absorption, oral supplementation may provide a method for restoring optimal concentrations.

2.4.1 Supplementation

Ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) are the most frequently used forms of oral supplement, with evidence recommending preferential use of cholecalciferol due to superior efficacy [8,24,81]. A number of regimens for supplementation of vitamin D2/D3 may be used, such as daily, weekly, or one-off high dose vitamin D3 (Stoss therapy). Varying levels of efficacy were reported in a recent systematic review [82]. When studies looking specifically at restoration of hypovitaminosis D were examined it was seen that while many regimens are effective at increasing serum concentrations, few report on longitudinal benefit or comment on the proportion who sustain sufficient levels (Table 2). No definitive dosing recommendations for daily, weekly, or Stoss therapy can be extrapolated from these studies (Table 2), or identified in reviews [14,61]. Attention should be paid to the research presented comparing different supplements and doses as are available in individual centers, and to evaluate which are effective for restoration and maintenance [24,53]. Patient preference should also be considered, with Stoss therapy reported as the patient’s preferred method [83], with this one-off dose reducing associated problems of ongoing treatment adherence and increased medication burden [52].

Table 2 Overview of studies reporting vitamin D supplementation for treatment of hypovitaminosis D in children with IBD.

Vitamin D supplementation may result in hypervitaminosis D, leading on to adverse effects related to high concentrations of calcium, phosphate, and paraththyroid hormone, and consequent complications such as renal calculi. However, these adverse effects were not seen in the identified literature among children with IBD using a range of supplementation regimens [43,51,52,53,81,83].

2.4.2 Testing Frequency

Screening for hypovitaminosis D should be carried out on children with CD or UC as both are at risk of deficiency [68]. While concentrations are lower at the time of diagnosis, many children remain deficient following treatment and follow up, and should be monitored accordingly [9]. Few papers provide recommendations relating to testing frequency, but screening is endorsed at diagnosis and then at least yearly, with particular attention to seasonality, as well as during active and asymptomatic periods [13].

2.4.3 Formal Guidelines

Scientific societies relating to Pediatric gastroenterology, hepatology and nutrition (PGHAN) are evident in all areas of the world, and bring together expertise to develop evidence based clinical practice guidelines. A small number of these organizations have published recommendations for the testing and treatment regimens relating to hypovitaminosis D for children with IBD. The North American Society (NASPGHAN) recommend measuring serum concentrations if there is significant bone mineral deficit, as well as checking yearly, however do not provide guidance on which specific concentrations should be used as cut-off for supplementation [85]. This review does provide comprehensive information on the types of vitamin D supplement available, nutritional sources, as well as dosing regimens for the treatment of rickets [85]. The European Society (ESPGHAN) have published guidance for children with UC, stating that there is insufficient evidence for supplementing all children on steroid therapy, but those with 25(OH)D concentrations less than 50 nmol/l should be provided with single high dose Stoss therapy (vitamin D3 300,000 to 500,000 IU) or regular supplementation (50,000 IU of vitamin D3 orally once weekly for 2 to 3 months, or 3 times weekly for 1 month), but they do not provide guidelines for testing frequency [86]. ESPGHAN have not provided recommendations in either of their consensus statements for the management of vitamin D in children with CD [87,88]. The British PGHAN (BSPGHAN) have comprehensive recommendations available to their members relating to monitoring, concentration cut-offs, and supplementation, but these are not published, nor intended to be used as a guideline [89].

3. Discussion

This review reports that vitamin D deficiency is prevalent among children with IBD and may be associated with worse disease activity and subsequent increased symptomatology that reduces oral intake and increases GI losses. The reported benefits of optimal vitamin D to bone health, the immune system, the gut, and clinical outcomes suggest that vitamin D may play a substantial role in ameliorating the effect of CD and UC among children. Consistent guidelines in relation to diagnostic testing frequency, optimal concentrations, and treatment of sub-optimal vitamin D, are lacking but this may reflect the dynamic changes and emerging evidence within this field in recent years.

The evaluation of vitamin D status should be established as standard-of-care for all children with IBD, regardless of any existing disease related or environmental factors, as many will satisfy at least one risk factor for insufficiency. Children with IBD undergo frequent testing as part of their disease monitoring so the additional assessment of vitamin D status should not pose a significant burden to them

While reducing disease activity, ensuring optimal dietary intake, and maximizing UV exposure, will contribute to maintaining vitamin D, many children with IBD will require restoration and maintenance using supplementation. Review of the current literature suggests that clearer guidance and strategies are needed for correcting hypovitaminosis D among children with IBD. However, the recent work highlighting the serum concentrations required for clinical benefit could be utilized as a therapeutic target for all children as opposed to supplementing on an individual basis as required.

The role of vitamin D as an inexpensive concomitant treatment warrants extensive investigation as there is still much to be learned about the vitamin D pathway and its capacity to affect the progression of CD and UC among children. The direction of future research may include investigation in to vitamin D metabolites as biomarkers, as well as measuring vitamin D absorption in order to optimize dosing and therapy, and further defining optimal concentrations for clinical benefit [12]. Work on the vitamin D axis, incorporating the vitamin D receptor and binding protein, may elucidate the importance of measuring these variables to determine their role in the pathogenesis of hypovitaminosis D and the clinical course of IBD, as well as being a target for treatment [39,47,90].

4. Conclusion

This review has added to the literature regarding this topic by providing an overview of the substantial research available, and highlighting that many aspects need further work to confirm relevance or determine importance. Due to the complex association between vitamin D and IBD, it remains unclear whether insufficiency in this population is causative of poor outcomes, or a consequence of the disease process. Large scale studies with well-established control groups are needed in order to elucidate this matter as the path of future research within this field will elicit heterogeneous outcomes until directionality is determined.

Author Contributions

All named authors made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work. All named authors revised the work critically for important intellectual content and gave approval for the final draft to be published. All named authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Competing Interests

The authors have declared that no competing interests exist.


  1. Sauer CG, Kugathasan S. Pediatric inflammatory bowel disease: Highlighting pediatric differences in IBD. Med Clin North Am. 2010; 94: 35-52. [CrossRef]
  2. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends. Inflamm Bowel Dis. 2011; 17: 423-439. [CrossRef]
  3. Sykora J, Pomahacova R, Kreslova M, Cvalinova D, Stych P, Schwarz J. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol. 2018; 24: 2741-2763. [CrossRef]
  4. Kelsen NJ, Baldassano NR. Inflammatory bowel disease: The difference between children and adults. Inflamm Bowel Dis. 2008; 14: S9-S11. [CrossRef]
  5. Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, et al. Natural history of Crohn's disease: Comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010; 16: 953-961. [CrossRef]
  6. Ruiz Castro PA, Yepiskoposyan H, Gubian S, Calvino-Martin F, Kogel U, Renggli K, et al. Systems biology approach highlights mechanistic differences between Crohn’s disease and ulcerative colitis. Sci Rep. 2021; 11: 11519. [CrossRef]
  7. Ramos GP, Papadakis KA. Mechanisms of disease: Inflammatory bowel diseases. Mayo Clin Proc. 2019; 94: 155-165. [CrossRef]
  8. Conklin LS, Oliva-Hemker M. Nutritional considerations in pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010; 4: 305-317. [CrossRef]
  9. Ehrlich S, Mark AG, Rinawi F, Shamir R, Assa A. Micronutrient deficiencies in children with inflammatory bowel diseases. Nutr Clin Pract. 2020; 35: 315-322. [CrossRef]
  10. Rempel J, Grover K, El-Matary W. Micronutrient deficiencies and anemia in children with inflammatory bowel disease. Nutrients. 2021; 13: 236. [CrossRef]
  11. Socha P, Ryzko J, Koletzko B, Celinska-Cedro D, Woynarowski M, Czubkowski P, et al. Essential fatty acid depletion in children with inflammatory bowel disease. Scand J Gastroenterol. 2005; 40: 573-577. [CrossRef]
  12. Gubatan J, Moss AC. Vitamin D in inflammatory bowel disease: More than just a supplement. Curr Opin Gastroenterol. 2018; 34: 217-225. [CrossRef]
  13. Leskovar D, Meštrović T, Barešić A, Kraljević I, Panek M, Paljetak HČ, et al. The role of vitamin D in inflammatory bowel disease-assessing therapeutic and preventive potential of supplementation and food fortification. Food Technol Biotechnol. 2018; 56: 455-463. [CrossRef]
  14. Saggese G, Vierucci F, Boot AM, Czech-Kowalska J, Weber G, Camargo CA, et al. Vitamin D in childhood and adolescence: An expert position statement. Eur J Pediatr. 2015; 174: 565-576. [CrossRef]
  15. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009; 20: 1807-1820. [CrossRef]
  16. Lips P, de Jongh RT, van Schoor NM. Trends in vitamin D status around the world. JBMR Plus. 2021; 5: e10585. [CrossRef]
  17. Gasparetto M, Guariso G. Crohn's disease and growth deficiency in children and adolescents. World J Gastroenterol. 2014; 20: 13219-13233. [CrossRef]
  18. Sentongo TA, Semaeo EJ, Stettler N, Piccoli DA, Stallings VA, Zemel BS. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am J Clin Nutr. 2002; 76: 1077-1081. [CrossRef]
  19. Hizarcioglu-Gulsen H, Kaplan JL, Moran CJ, Israel EJ, Lee H, Winter H. The impact of vitamin D on response to anti-tumor necrosis factor-α therapy in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2021; 72: e125-e131. [CrossRef]
  20. Nielsen OH, Rejnmark L, Moss AC. Role of vitamin D in the natural history of inflammatory bowel disease. J Crohns Colitis. 2018; 12: 742-752. [CrossRef]
  21. Priemel M, von Domarus C, Klatte TO, Kessler S, Schlie J, Meier S, et al. Bone mineralization defects and vitamin D deficiency: Histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res. 2010; 25: 305-312. [CrossRef]
  22. Stagi S, Cavalli L, Iurato C, Seminara S, Brandi ML, de Martino M. Bone metabolism in children and adolescents: Main characteristics of the determinants of peak bone mass. Clin Cases Miner Bone Metab. 2013; 10: 172-179.
  23. Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord. 2017; 18: 153-165. [CrossRef]
  24. Pappa HM, Grand RJ, Gordon CM. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis. 2006; 12: 1162-1174. [CrossRef]
  25. Gordon RJ, Gordon CM. Bone health in pediatric patients with IBD: What is new? Curr Osteoporos Rep. 2021; 19: 429-435. [CrossRef]
  26. Thompson MR, Dean MD, Goldberg JS, Kwasny BM, Langman AC, Janicki AJ. Vitamin D insufficiency and fracture risk in urban children. J Pediatr Orthop. 2017; 37: 368-373. [CrossRef]
  27. Wang N, Chen Y, Ji J, Chang J, Yu S, Yu B. The relationship between serum vitamin D and fracture risk in the elderly: A meta-analysis. J Orthop Surg Res. 2020; 15: 81. [CrossRef]
  28. Salehi V, Small L, Yau M, Sockolow R. Vitamin D deficiency and abnormal bone density in pediatric patients with Inflammatory Bowel Disease: P-160. Inflamm Bowel Dis. 2011; 17: S61. [CrossRef]
  29. El-Matary W, Sikora S, Spady D. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci. 2011; 56: 825-829. [CrossRef]
  30. Badalyan V, Townsend S, Fish S, Leibowitz I. Vitamin D levels and bone density of children with IBD. Inflamm Bowel Dis. 2011; 17: S40. [CrossRef]
  31. Sylvester FA, Wyzga N, Hyams JS, Davis PM, Lerer T, Vance K, et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 42-50. [CrossRef]
  32. Hradsky O, Soucek O, Maratova K, Matyskova J, Copova I, Zarubova K, et al. Supplementation with 2000 IU of cholecalciferol is associated with improvement of trabecular bone mineral density and muscle power in pediatric patients with IBD. Inflamm Bowel Dis. 2017; 23: 514-523. [CrossRef]
  33. Benchimol EI, Ward LM, Gallagher JC, Rauch F, Barrowman N, Warren J, et al. Effect of calcium and vitamin D supplementation on bone mineral density in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007; 45: 538-545. [CrossRef]
  34. Harpavat M, Keljo DJ. Perspectives on osteoporosis in pediatric inflammatory bowel disease. Curr Gastroenterol Rep. 2003; 5: 225-232. [CrossRef]
  35. Sylvester FA, Hyams JS, Justinich CJ, Zeiter DK, Harris K, Avolio J, et al. Longitudinal follow-up of bone mineral density in children with Crohn's disease from the time of diagnosis. Gastroenterology. 2000; 118: A887. [CrossRef]
  36. Winzenberg T, Powell S, Shaw KA, Jones G. Effects of vitamin D supplementation on bone density in healthy children: Systematic review and meta-analysis. BMJ. 2011; 342: c7254. [CrossRef]
  37. Ardesia M, Ferlazzo G, Fries W. Vitamin D and inflammatory bowel disease. Biomed Res Int. 2015; 2015: 470805. [CrossRef]
  38. Malaguarnera L. Vitamin D and microbiota: Two sides of the same coin in the immunomodulatory aspects. Int Immunopharmacol. 2020; 79: 106112. [CrossRef]
  39. Battistini C, Ballan R, Herkenhoff ME, Saad SMI, Sun J. Vitamin D modulates intestinal microbiota in inflammatory bowel diseases. Int J Mol Sci. 2020; 22: 362. [CrossRef]
  40. Meeker S, Seamons A, Maggio-Price L, Paik J. Protective links between vitamin D, inflammatory bowel disease and colon cancer. World J Gastroenterol. 2016; 22: 933-948. [CrossRef]
  41. Yoon JY. Nutritional approach as therapeutic manipulation in inflammatory bowel disease. Intest Res. 2019; 17: 463-475. [CrossRef]
  42. Del Pinto R, Pietropaoli D, Chandar AK, Ferri C, Cominelli F. Association between inflammatory bowel disease and vitamin D deficiency: A systematic review and meta-analysis. Inflamm Bowel Dis. 2015; 21: 2708-2717. [CrossRef]
  43. El Amrousy D, El Ashry H, Hodeib H, Hassan S. Vitamin D in children with inflammatory bowel disease: A randomized controlled clinical trial. J Clin Gastroenterol. 2021; 55: 815-820. [CrossRef]
  44. Bafutto M, Oliveira EC, Rezende Filho J. Use of vitamin D with anti-tumor necrosis factor therapy for Crohn’s disease. Gastroenterol Res. 2020; 13: 101-106. [CrossRef]
  45. Garg M, Rosella O, Lubel JS, Gibson PR. Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2013; 19: 2634-2643. [CrossRef]
  46. Scolaro BL, Barretta C, Matos CH, Malluta EF, Almeida IBTd, Braggio LD, et al. Deficiency of vitamin D and its relation with clinical and laboratory activity of inflammatory bowel diseases. J Coloproctol. 2018; 38: 99-104. [CrossRef]
  47. Strisciuglio C, Cenni S, Giugliano FP, Erasmo M, Cirillo G, Martinelli M, et al. The role of inflammation on vitamin D axis in a cohort of pediatric patients with inflammatory bowel disease. Dig Liver Dis. 2017; 49: e260. [CrossRef]
  48. Pappa HM, Gordon CM, Saslowsky TM, Zholudev A, Horr B, Shih MC, et al. Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics. 2006; 118: 1950-1961. [CrossRef]
  49. Safdi A, D'Mello S, Walters TD, Griffiths AM, Denson L. S2003 serum vitamin D level and disease activity in pediatric inflammatory bowel disease. Gastroenterology. 2010; 5: S-299. [CrossRef]
  50. Kim S, Kang Y, Park S, Koh H, Kim S. Association of vitamin D with inflammatory bowel disease activity in pediatric patients. J Korean Med Sci. 2019; 34: e204. [CrossRef]
  51. Martin NG, Rigterink T, Adamji M, Wall CL, Day AS. Single high-dose oral vitamin D3 treatment in New Zealand children with inflammatory bowel disease. Transl Pediatr. 2019; 8: 35-41. [CrossRef]
  52. Shepherd SD, Day TA, Leach JS, Lopez AR, Messenger AR, Woodhead AH, et al. Single high-dose oral vitamin D3 therapy (stoss): A solution to vitamin d deficiency in children with inflammatory bowel disease? J Pediatr Gastroenterol Nutr. 2015; 61: 411-414. [CrossRef]
  53. Pappa HM, Mitchell PD, Jiang H, Kassiff S, Filip-Dhima R, DiFabio D, et al. Maintenance of optimal vitamin D status in children and adolescents with inflammatory bowel disease: A randomized clinical trial comparing two regimens. J Clin Endocrinol Metab. 2014; 99: 3408-3417. [CrossRef]
  54. Li XX, Liu Y, Luo J, Huang ZD, Zhang C, Fu Y. Vitamin D deficiency associated with Crohn’s disease and ulcerative colitis: A meta-analysis of 55 observational studies. J Transl Med. 2019; 17: 323. [CrossRef]
  55. Li J, Chen N, Wang D, Zhang J, Gong X. Efficacy of vitamin D in treatment of inflammatory bowel disease: A meta-analysis. Medicine. 2018; 97: e12662. [CrossRef]
  56. Guzman-Prado Y, Samson O, Segal JP, Limdi JK, Hayee BH. Vitamin D therapy in adults with inflammatory bowel disease: A systematic review and meta-analysis. Inflamm Bowel Dis. 2020; 26: 1819-1830. [CrossRef]
  57. Limketkai B, Kavuru R, Parian AM, Kazzi ESA, Tripathi K, Hutfless SM. Su1853-vitamin D for the treatment of inflammatory bowel diseases: A Cochrane review and meta-analysis. Gastroenterology. 2018; 154: S-607-S-608. [CrossRef]
  58. Guo Y, Zhang T, Wang Y, Liu R, Chang M, Wang X. Effects of oral vitamin D supplementation on inflammatory bowel disease: A systematic review and meta-analysis. Food Funct. 2021; 12: 7588-7606. [CrossRef]
  59. Zator ZA, Cantu SM, Konijeti GG, Nguyen DD, Sauk J, Yajnik V, et al. Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-α therapy in inflammatory bowel diseases. JPEN J Parenter Enteral Nutr. 2014; 38: 385-391. [CrossRef]
  60. Winter RW, Collins E, Cao B, Carrellas M, Crowell AM, Korzenik JR. Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2017; 45: 653-659. [CrossRef]
  61. Taylor SN. Vitamin D in toddlers, preschool children, and adolescents. Ann Nutr Metab. 2020; 76: 30-41. [CrossRef]
  62. Płudowski P, Karczmarewicz E, Bayer M, Carter G, Chlebna-Sokół D, Czech-Kowalska J, et al. Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe-recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Pol. 2013; 64: 319-327. [CrossRef]
  63. Paxton GA, Teale GR, Nowson CA, Mason RS, McGrath JJ, Thompson MJ, et al. Vitamin D and health in pregnancy, infants, children and adolescents in Australia and New Zealand: A position statement. Med J Aust. 2013; 198: 142-143. [CrossRef]
  64. Braegger C, Campoy C, Colomb V, Decsi T, Domellof M, Fewtrell M, et al. Vitamin D in the healthy European paediatric population. J Pediatr Gastroenterol Nutr. 2013; 56: 692-701. [CrossRef]
  65. Alkhouri RH, Hashmi H, Baker RD, Gelfond D, Baker SS. Vitamin and mineral status in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013; 56: 89-92. [CrossRef]
  66. Jin HY, Lim JS, Lee Y, Choi Y, Oh SH, Kim KM, et al. Growth, puberty, and bone health in children and adolescents with inflammatory bowel disease. BMC Pediatr. 2021; 21: 35. [CrossRef]
  67. Levin AD, Wadhera V, Leach ST, Woodhead HJ, Lemberg DA, Czarina Mendoza-Cruz A, et al. Vitamin D deficiency in children with inflammatory bowel disease. Dig Dis Sci. 2011; 56: 830-836. [CrossRef]
  68. Pappa HM, Langereis EJ, Grand RJ, Gordon CM. Prevalence and risk factors for hypovitaminosis d in young patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011; 53: 361-364. [CrossRef]
  69. Prosnitz AR, Leonard MB, Shults J, Zemel BS, Hollis BW, Denson LA, et al. Changes in vitamin D and parathyroid hormone metabolism in incident pediatric Crohnʼs disease. Inflamm Bowel Dise. 2013; 19: 45-53. [CrossRef]
  70. Tran B-CR, Huang GS, Jantchou P. Risk factors for vitamin D deficiency in children with Crohn's disease or ulcerative colitis in Canada. Gastroenterology. 2017; 152: S785. [CrossRef]
  71. Veit LE, Maranda L, Fong J, Benjamin Udoka N. The vitamin D status in inflammatory bowel disease. PLoS One. 2014; 9: e101583. [CrossRef]
  72. Reich KM, Fedorak RN, Madsen K, Kroeker KI. Vitamin D improves inflammatory bowel disease outcomes: Basic science and clinical review. World J Gastroenterol. 2014; 20: 4934-4947. [CrossRef]
  73. Miraglia del Giudice M, Indolfi C, Strisciuglio C. Vitamin D: Immunomodulatory aspects. J Clin Gastroenterol. 2018; 52: S86-S88. [CrossRef]
  74. Limketkai BN, Bayless TM, Brant SR, Hutfless SM. Lower regional and temporal ultraviolet exposure is associated with increased rates and severity of inflammatory bowel disease hospitalisation. Aliment Pharmacol Ther. 2014; 40: 508-517. [CrossRef]
  75. Schultz M, Butt AG. Is the north to south gradient in inflammatory bowel disease a global phenomenon? Expert Rev Gastroenterol Hepatol. 2014; 6: 445-447. [CrossRef]
  76. Nerich V, Monnet E, Etienne A, Louafi S, Ramée C, Rican S, et al. Geographical variations of inflammatory bowel disease in France: A study based on national health insurance data. Inflamm Bowel Dis. 2006; 12: 218-226. [CrossRef]
  77. Ng SC, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV, Tysk C, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013; 62: 630-649. [CrossRef]
  78. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2017; 390: 2769-2778. [CrossRef]
  79. Lopez NR, Evans MH, Appleton BL, Bishop SJ, Chin SS, Mouat SS, et al. Point prevalence of pediatric inflammatory bowel disease in New Zealand in 2015: Initial results from the PINZ study. Inflamm Bowel Dis. 2017; 23: 1418-1424. [CrossRef]
  80. Bahrami A, Sadeghnia HR, Tabatabaeizadeh SA, Bahrami-Taghanaki H, Behboodi N, Esmaeili H, et al. Genetic and epigenetic factors influencing vitamin D status. J Cell Physiol. 2018; 233: 4033-4043. [CrossRef]
  81. Pappa HM, Mitchell PD, Jiang H, Kassiff S, Filip-Dhima R, DiFabio D, et al. Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: A randomized clinical trial comparing three regimens. J Clin Endocrinol Metab. 2012; 97: 2134-2142. [CrossRef]
  82. Rigterink T, Appleton L, Day AS. Vitamin D therapy in children with inflammatory bowel disease: A systematic review. World J Clin Pediatr. 2019; 8: 1-14. [CrossRef]
  83. Lee R, Maltz RM, Crandall WV, Plogsted SW, Shaikhkhalil AK, Bowden SA, et al. Single high-dose vitamin D3 supplementation in pediatric patients with inflammatory bowel disease and hypovitaminosis D. J Pediatr Gastroenterol Nutr. 2020; 70: e77-e80. [CrossRef]
  84. Simek RZ, Prince J, Syed S, Sauer CG, Martineau B, Hofmekler T, et al. Pilot study evaluating efficacy of 2 regimens for hypovitaminosis D repletion in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2016; 62: 252-258. [CrossRef]
  85. Rufo PA, Denson LA, Sylvester FA, Szigethy E, Sathya P, Lu Y, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr. 2012; 55: 93-108. [CrossRef]
  86. Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, Carpi JMd, Bronsky J, et al. Management of paediatric ulcerative colitis, part 1: Ambulatory care- an evidence-based guideline from ECCO and ESPGHAN. J Pediatr Gastroenterol Nutr. 2018; 67: 257-291. [CrossRef]
  87. Rheenen vP, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The medical management of paediatric Crohn's disease: An ECCO-ESPGHAN guideline update. J Crohns Colitis. 2020; 15: 171-194. [CrossRef]
  88. Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014; 8: 1179-1207. [CrossRef]
  89. IBD working group of BSPGHAN. Vitamin D in paediatric inflammatory bowel disease [Internet]. London: BSPGHAN; 2019. Available from:
  90. Del Pinto R, Ferri C, Cominelli F. Vitamin D axis in inflammatory bowel diseases: Role, current uses and future perspectives. Int J Mol Sci. 2017; 18: 2360. [CrossRef]
Download PDF Download Citation
0 0